Aurobindo Pharma’s American arm Aurobindo Pharma USA, Inc. has initiated a voluntary recall of Gabapentin capsules, which are used in the treatment of epilepsy, of a particular lot in the US market as some of the capsules were found to be empty. The empty capsules could have adverse health consequences that can range from having no effect to a short term reduction in efficiency.
The company received the American drug regulator's approval to manufacture and market the product in October 2011. The affected Gabapentin lot, GESB14011-A, expires on December 2015 and is packaged in 100-count bottles.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
